



**(301) 366-4960**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Items.**

On December 8, 2015, Neuralstem, Inc. (the “Company”) announced the publication of Phase 1b data in *Molecular Psychiatry* for their lead small molecule drug, NSI-189 in patients with major depressive disorder. The report showed that NSI-189, benzylpiperazine-aminiopyridine compound with neurogenic and synaptogenic mechanism of action, was well tolerated for 28 days at escalating doses. A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit**

| <b>No.</b> | <b>Description</b>                   |
|------------|--------------------------------------|
| 99.01      | Press Release Dated December 8, 2015 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 8, 2015 Neuralstem, Inc.

/s/ Richard Garr  
By: Richard Garr  
Chief Executive Officer

**INDEX OF EXHIBITS**

**Exhibit**

| <b>No.</b> | <b>Description</b>                   |
|------------|--------------------------------------|
| 99.01      | Press Release Dated December 8, 2015 |